Varian Biopharmaceuticals to Present at the Inflection Partners "Excellence in Execution" Conference on November 16th and 17th
PrAtlas/22616646

NAPLES, Fla. - PrAtlas -- Varian Biopharmaceuticals, Inc. ("VarianBio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, today announced its President and CEO, Jeffrey Davis, will be presenting at the Inflection Partners Fall Investment Conference entitled "Excellence in Execution."

The Inflection Partners Fall Conference will take place virtually on November 16-17, 2021, and Mr. Davis is scheduled to present at 2:40 pm ET on Tuesday, November 16, 2021. To register for the Inflection Partners conference, please visit:  www.inflectionpartnersllc.com/fallconference

This event will feature more than 25 companies, ranging from disruptive seed stage startups to $1bn+ market cap public companies. This year's conference supports the Travis Manion Foundation (TSF), which strives to unite and strengthen communities by training, developing, and highlighting the role models that lead them. Travis Manion was an experienced and decorated Marine who was killed in action on April 29, 2007, in Iraq. The TSF develops programs, training opportunities, and events designed to empower veterans and families of the fallen while inspiring them to pass their values on to the next generation and the community at large. For more information, please visit travismanion.org.

More on PrAtlas

• Bettingbladet releases H1 2026 report on the Swedish online gambling market
• Garage door installation or repair in Minnesota? Which makes more sense for your family?
• Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
• European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
• VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball

About Varian Biopharmaceuticals, Inc.

Varian Biopharmaceuticals, Inc. ("VarianBio") is private precision oncology company developing novel therapeutics for the treatment of cancer. Precision oncology, whereby physicians use DNA testing to look for genetic mutations of the unique tumors, holds the promise of more targeted treatment recommendations with therapies designed to fight specific tumor types. Varian Bio is developing a best-in-class high-potency, specific atypical protein kinase C iota ("aPKCi") inhibitor for the treatment of various tumor types in multiple formulations. Recent scientific publications have characterized aPKCi as a bonafide oncogene whose activity may play a fundamental role in the regulation of cancer-associated transcription factors including GLI-1 and K-RAS.  Varian Bio's lead drug candidate, VAR-101, being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors where studies have shown potent aPKCi inhibition would be impactful, including non-small cell lung cancer (NSCLC), pancreatic cancer and colorectal cancer.  Additionally, Varian Bio is seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. For more information, please visit www.varianbio.com.

More on PrAtlas

• Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
• Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
• Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
• Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
• FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)

Forward-Looking Statements – Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek" or "project" or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and the expectations expressed in forward-looking statements may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Contacts:

Investors and Media
Jeffrey B. Davis
President & CEO
jdavis@varianbio.com